ADRB1 and fetal growth restriction: Therefore, we investigated whether selective ADRβ1 and ADRβ3 antagonists combined with an ADRβ2 agonist will normalize the predicted adrenergic dysregulation and improve early outcomes in growth, insulin secretion and action, and cardiovascular parameters in young lambs that were IUGR at birth.